B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Growth Forecast: Exploring Trends and Opportunities for the Next Decade
Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.
What fueled the previous growth in the b-cell maturation antigen (bcma) targeted therapies market?
The market for therapies targeting the B-cell maturation antigen (BCMA) has seen an impressive expansion in recent times. It is expected to amplify from $12.17 billion in 2024 to $15.21 billion by 2025, displaying a compound annual growth rate (CAGR) of 25.0%. This robust growth during the historic period is credited to increased concentration on hematologic malignancies, escalated investments in oncology research, surging requirement for personalized medicine, heightened utilization of CAR-T cell therapies, and an uptick in healthcare spending.
What will be the b-cell maturation antigen (bcma) targeted therapies market size in the future?
In the forthcoming years, a significant expansion is anticipated in the B-cell maturation antigen (BCMA) targeted therapies market. By 2029, it is predicted to escalate to a worth of $36.66 billion, with a compound annual growth rate (CAGR) of 24.6%. The projected growth can be credited to the increasing emphasis on cancer research, shifts towards targeting specific molecular indicators, prevalence of cancers, boost in biotechnology investments, and rising application of cell and gene therapies. The forecast period is marked by key trends such as the innovation of the CRISPR technology, progress in gene-editing technologies, advancements in the next-generation car-t cell therapies, enhancements in targeted antibody-drug conjugates, and the creation of off-the-shelf treatments.
Get your b-cell maturation antigen (bcma) targeted therapies market report here!
What main drivers are fueling expansion in the b-cell maturation antigen (bcma) targeted therapies market?
The increasing cases of multiple myeloma cancer are forecasted to stimulate advancements in the b-cell maturation antigen (BCMA) targeted therapies market. Multiples myeloma, a cancer type predominantly impacting plasma cells, essential parts of the immune system responsible for generating antibodies, observes rising incidence due to various factors including, growing elderly population, advancements in diagnosis methods, and differential healthcare accessibility. The BCMA-oriented therapies play a key role in treating multiple myeloma by concentrating on and curbing the malignant plasma cells expressing BCMA. These therapies provide an optimistic platform for a more precise treatment. To illustrate, the American Cancer Society noted in August 2024 that around 35,780 fresh cases of multiple myeloma were identified in the United States in 2024, of which 19,520 were men and 16,260 women. The anticipated death count stands at about 12,540, with 7,020 men and 5,520 women. Thus, the augmenting cases of multiple myeloma are fueling the growth of the b-cell maturation antigen (BCMA) targeted therapies market.
What key areas define the segmentation of the global b-cell maturation antigen (bcma) targeted therapies market?
The B-cell maturation antigen (BCMA) targeted therapies market covered in this report is segmented –
1) By Product Type: Antibody Drug Conjugates, Chimeric Antigen Receptor T (CAR-T)-Cell Therapy, Bispecific Antibodies
2) By Indication Type: Acute Lymphoblastic Leukemia, Multiple Myeloma
3) By End User: Hospitals, Specialty Clinics, Home Care Settings
Subsegments:
1) By Antibody Drug Conjugates: BCMA-Targeted ADCs (Antibody-Drug Conjugates), Linker-Payload Technology-Based BCMA ADCs
2) By Chimeric Antigen Receptor T (CAR-T)-Cell Therapy: BCMA CAR-T Cells (Autologous), Allogeneic BCMA CAR-T Cells
3) By Bispecific Antibodies: BCMA x CD3 Bispecific Antibodies, BCMA x CD28 Bispecific Antibodies
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20718&type=smp
Who are the dominant players expanding their reach in the b-cell maturation antigen (bcma) targeted therapies market?
Major companies operating in the B-cell maturation antigen (BCMA) targeted therapies market are Bristol Myers Squibb Company, Novartis, GlaxoSmithKline (GSK), Takeda Pharmaceutical Company Limited, Amgen Inc, Regeneron Pharmaceuticals, Beigene, Arcellx Inc, Poseida Therapeutics, Legend Biotech Corporation, Cartesian Therapeutics, Juno Therapeutics, Sutro Biopharma Inc, CARsgen Therapeutics, Precision BioSciences, Eureka Therapeutics Inc, Cellectis, Teneobio Inc., Janssen Pharmaceuticals Companies, Allogene Therapeutics, Affimed, Bluebird Bio Inc.
What are the key trends shaping the future of the b-cell maturation antigen (bcma) targeted therapies market?
Major companies operating in the B-cell maturation antigen (BCMA) targeted therapies market are focusing on developing innovative treatments such as CAR-T cell therapy to enhance the efficacy and precision of targeting cancer cells. CAR-T cell therapy is a type of immunotherapy that involves modifying a patient’s T cells to express chimeric antigen receptors (CARs) to target and kill cancer cells. For instance, in April 2024, Johnson & Johnson, a US-based pharmaceutical industry company, received U.S. Food and Drug Administration (FDA) approval for CARVYKTI. CARVYKTI (ciltacabtagene autoleucel) is a BCMA-targeted, genetically modified autologous T-cell immunotherapy for treating adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy and are refractory to lenalidomide.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20718
Which regions are emerging as leaders in the b-cell maturation antigen (bcma) targeted therapies market?
North America was the largest region in the B-cell maturation antigen (BCMA) targeted therapies market in 2024. The regions covered in the B-cell maturation antigen (BCMA) targeted therapies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Browse Through More Similar Reports By The Business Research Company:
Diffuse Large B-Cell Lymphoma Therapeutics Global Market Report 2025
Brain Tumor Drugs Global Market Report 2025
https://thebusinessresearchcompany.com/report/brain-tumor-drugs-global-market-report
Tumor Ablation Therapy Devices Global Global Market Report 2025
https://thebusinessresearchcompany.com/report/tumor-ablation-therapy-devices-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
